3 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
Follow Bai-Rong Xia: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer SunitinibăOlaparibăTolilizumab - Ovary Cancer | Phase 2 | Recruiting | Bai-Rong Xia | 35 | 2026-06-01 | 2026-06-25 |
| Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer Propranolol Hydrochloride, Paclitaxel liposome, Carboplatin - Ovarian Cancer | Phase 2 | Recruiting | Bai-Rong Xia | 136 | 2025-06-20 | 2026-06-30 |
| Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer Pamiparib, Surufatinib - Ovarian Cancer | Phase 2 | Recruiting | Bai-Rong Xia | 37 | 2022-11-06 | 2026-10-02 |
Carboplatin (1) · Propranolol (1) · pamiparib (1) · surufatinib (1)
China (3)
Wenjing Jiang (1)